Annual Retained Earnings
-$66.90 M
-$19.03 M-39.75%
31 December 2023
Summary:
Inhibikase Therapeutics annual retained earnings is currently -$66.90 million, with the most recent change of -$19.03 million (-39.75%) on 31 December 2023. During the last 3 years, it has fallen by -$51.87 million (-345.07%). IKT annual retained earnings is now -935.50% below its all-time high of -$6.46 million, reached on 31 December 2018.IKT Retained Earnings Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Retained Earnings
-$82.29 M
-$5.78 M-7.55%
30 September 2024
Summary:
Inhibikase Therapeutics quarterly retained earnings is currently -$82.29 million, with the most recent change of -$5.78 million (-7.55%) on 30 September 2024. Over the past year, it has dropped by -$19.57 million (-31.19%). IKT quarterly retained earnings is now -575.39% below its all-time high of -$12.18 million, reached on 31 December 2019.IKT Quarterly Retained Earnings Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IKT Retained Earnings Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -39.8% | -31.2% |
| 3 y3 years | -345.1% | -232.1% |
| 5 y5 years | -935.5% | - |
IKT Retained Earnings High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -345.1% | at low | -232.1% | at low |
| 5 y | 5 years | -935.5% | at low | -575.4% | at low |
| alltime | all time | -935.5% | at low | -575.4% | at low |
Inhibikase Therapeutics Retained Earnings History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | -$82.29 M(+7.6%) |
| June 2024 | - | -$76.51 M(+6.9%) |
| Mar 2024 | - | -$71.55 M(+7.0%) |
| Dec 2023 | -$66.90 M(+39.7%) | -$66.90 M(+6.7%) |
| Sept 2023 | - | -$62.72 M(+7.9%) |
| June 2023 | - | -$58.13 M(+11.0%) |
| Mar 2023 | - | -$52.35 M(+9.4%) |
| Dec 2022 | -$47.87 M | -$47.87 M(+9.8%) |
| Sept 2022 | - | -$43.59 M(+11.5%) |
| June 2022 | - | -$39.10 M(+13.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | -$34.46 M(+15.6%) |
| Dec 2021 | -$29.82 M(+98.4%) | -$29.82 M(+20.3%) |
| Sept 2021 | - | -$24.78 M(+22.0%) |
| June 2021 | - | -$20.30 M(+14.9%) |
| Mar 2021 | - | -$17.67 M(+17.5%) |
| Dec 2020 | -$15.03 M(+23.4%) | -$15.03 M(+8.7%) |
| Sept 2020 | - | -$13.82 M(+5.1%) |
| June 2020 | - | -$13.15 M(+3.3%) |
| Mar 2020 | - | -$12.73 M(+4.5%) |
| Dec 2019 | -$12.18 M(+88.6%) | -$12.18 M |
| Dec 2018 | -$6.46 M | - |
FAQ
- What is Inhibikase Therapeutics annual retained earnings?
- What is the all time high annual retained earnings for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics annual retained earnings year-on-year change?
- What is Inhibikase Therapeutics quarterly retained earnings?
- What is the all time high quarterly retained earnings for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics quarterly retained earnings year-on-year change?
What is Inhibikase Therapeutics annual retained earnings?
The current annual retained earnings of IKT is -$66.90 M
What is the all time high annual retained earnings for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high annual retained earnings is -$6.46 M
What is Inhibikase Therapeutics annual retained earnings year-on-year change?
Over the past year, IKT annual retained earnings has changed by -$19.03 M (-39.75%)
What is Inhibikase Therapeutics quarterly retained earnings?
The current quarterly retained earnings of IKT is -$82.29 M
What is the all time high quarterly retained earnings for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high quarterly retained earnings is -$12.18 M
What is Inhibikase Therapeutics quarterly retained earnings year-on-year change?
Over the past year, IKT quarterly retained earnings has changed by -$19.57 M (-31.19%)